Antisense oligonucleotide therapy for neurodegenerative disease. - Wikidata - wikimedia - TriplyDB

Antisense oligonucleotide therapy for neurodegenerative disease.

Antisense oligonucleotide therapy for neurodegenerative disease.

http://www.wikidata.org/entity/Q34830633

about

From animal models to human disease: a genetic approach for personalized medicine in ALS Toward precision medicine in amyotrophic lateral sclerosis Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain Applications of CRISPR-Cas systems in neuroscience Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery Involvement of long noncoding RNAs in diseases affecting the central nervous system Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis Induced pluripotent stem cells from ALS patients for disease modeling Antisense oligonucleotides: treating neurodegeneration at the level of RNA Identification and Characterization of the V(D)J Recombination Activating Gene 1 in Long-Term Memory of Context Fear Conditioning.Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides.Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation RNA-targeted Therapeutics for ALS Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients Targeting several CAG expansion diseases by a single antisense oligonucleotide RNA and disease Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model.Pharmacology, pharmacokinetics, and metabolism of the DNA-decoy AYX1 for the prevention of acute and chronic post-surgical pain Redox modifier genes and pathways in amyotrophic lateral sclerosis.Modelling amyotrophic lateral sclerosis: progress and possibilities Whole transcriptome analysis: what are we still missing?Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis.A high-throughput screen to identify inhibitors of SOD1 transcription.Genetics and ALS: Cause for Optimism.Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model Mutant SOD1 knockdown in all cell types ameliorates disease in G85R SOD1 mice with a limited additional effect over knockdown restricted to motor neurons Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain.Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.Antisense therapy in neurology Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.

P2860

Q26741250-88E29AF1-1A79-4FC9-811B-6B011750B779 Q26764950-8E89A589-3413-44E1-A14C-73A0C8E95153 Q26770355-3AD33D74-581B-479D-907F-BB54F0FB4A87 Q26776515-973AE83D-59CD-486E-B74D-B9CD4D0540AA Q26830637-AB5BFD91-376E-4114-8243-5A2E84D77033 Q26852160-B33A501A-8409-47B5-831C-CE4ED8ADC0B4 Q26863439-73F35B1D-4321-49F3-A59D-3B2F0ED21648 Q27000647-CBBF1E4D-95EB-4818-9D3F-C045D1A6227E Q27007056-0F68585B-5BBA-4AD2-AD88-7369BAFF0CDC Q27314742-2F4FCE57-7A03-4325-8BC1-D09F9FBB4431 Q27314897-962CCEC6-9AF9-41B9-ACBC-128A44867036 Q27324779-BDF781C2-DA3D-4453-805F-119780FC972F Q28083290-5AD3492C-09CD-42BE-90AD-BC42232B99A6 Q28542911-1C72F76B-D265-45C7-B2B3-F365F79085C6 Q28740870-6D5696EA-CE63-43C4-B2C8-CFCC5829FC7F Q29615183-D0B79ABD-065F-4683-9A9E-FB79C15E6D73 Q30843477-E54E09D2-DC4A-4C93-9889-62EB69457AF7 Q33610526-DAF4E60C-8053-48AD-B91B-52E75F964FB0 Q33742737-536A0CB8-900E-42B6-AC79-936298CDDE43 Q33746289-A7520D70-F708-4C78-A9AB-ACC34B76BEE9 Q33783513-2F61B091-A27B-4E45-94DB-80A27CFC96B6 Q33833426-9533D919-5C73-4ED3-B7B5-BF35D81B8DF9 Q33850895-FCC975FA-A683-4FA4-BF98-E212BB075182 Q33882732-72E92685-494D-47C5-824F-F41712D6D73D Q34001049-AB8E2C94-6470-4503-BC02-C0A5DD9C9BBD Q34030144-CF954EDC-AE91-46F7-A0B9-785AB1214D0C Q34036108-524DD217-7D53-45A8-8F45-C57ADBD60B58 Q34168139-2C044DF9-504B-47CE-AF74-162DD9167358 Q34221351-DBEF69C9-CF5B-4215-BF12-D0346A1DB510 Q34222849-E8349311-3D44-4421-9961-E8AD91A0EB20 Q34234969-3F8460D0-BF81-4CF9-8A29-0A53C500F378 Q34283652-6ED5BAD6-7D86-48AD-955D-36028EDAF412 Q34348297-77E3A1CA-46CC-4A8F-AD2B-B1BC15FD074F Q34401653-3898C4EC-A328-4E3C-9582-5237323F21C8 Q34492631-AF15D3D8-E429-4BEE-9175-2B47AC10AE97 Q34499502-AF0F766A-70F2-4D86-93A3-2C1591B9D8B0 Q34538171-9E962FBA-944A-4833-B40A-8288A3FF7D65 Q34540158-56B3C0D3-FBA4-4513-83FE-334461E22DA6 Q34608717-0319E7DA-019C-41B4-BE18-16996C30A811 Q34610922-84DB4DB1-B13E-4E7F-AE7B-C46B234E28C7

P2860

Antisense oligonucleotide therapy for neurodegenerative disease.

http://www.wikidata.org/entity/Q34830633

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Antisense oligonucleotide therapy for neurodegenerative disease.

@ast

Antisense oligonucleotide therapy for neurodegenerative disease.

@en

Antisense oligonucleotide therapy for neurodegenerative disease.

@nl

type

label

Antisense oligonucleotide therapy for neurodegenerative disease.

@ast

Antisense oligonucleotide therapy for neurodegenerative disease.

@en

Antisense oligonucleotide therapy for neurodegenerative disease.

@nl

prefLabel

Antisense oligonucleotide therapy for neurodegenerative disease.

@ast

Antisense oligonucleotide therapy for neurodegenerative disease.

@en

Antisense oligonucleotide therapy for neurodegenerative disease.

@nl

P1433

Q34830633-5DBC44C7-6784-4BB9-BD0D-FB1DFC0BF4EE

P1476

Q34830633-1CCC1AB2-8BE4-4EF3-9558-9228AA17086D

P2093

Q34830633-1ED8B7FB-F9E7-4A81-AD29-63FD8D26612D

Q34830633-26FCB309-6733-4FB9-881F-05AFA89B59E0

Q34830633-2CB2F847-9019-4DC2-83FF-15860AAFAE6B

Q34830633-5EB1ABE7-F186-4C8D-A829-9ECCA941D97B

Q34830633-8D02C2BD-CD66-43E5-B276-66E457F33770

Q34830633-9D4EA863-2872-40F9-8877-4F0AC5159A5D

Q34830633-9FBCF706-30AA-44A6-9D11-539AFF3A85F1

Q34830633-A8C92C6D-83A7-4C40-9994-A06EE407300F

Q34830633-C1A333E1-6F22-4051-BE79-9C70366FADD5

Q34830633-D32C0655-0FA9-4132-9701-1607322A2BAD

P2860

Q34830633-013BB2DA-C6AA-45F2-80DA-1EA5A5EA7A2D

Q34830633-0732B0BA-6196-4969-8555-96E8ACC8DD1B

Q34830633-0F4336A2-42C9-4735-884D-EA5D07ED381A

Q34830633-1037B3F1-B338-4B43-9387-0A89B0DFFE52

Q34830633-116F1E86-A932-421F-8095-743359E7404E

Q34830633-17145CE8-1104-46E4-B3A4-8863BFFEF680

Q34830633-238BCC2B-6396-49F7-A31E-AB3D800841C2

Q34830633-28F185CA-A46E-4113-B43B-9655D7CC5C23

Q34830633-2B60B84A-6C2D-42E3-B35E-2D620F66C601

Q34830633-2D04B9C6-1B89-42C6-965B-05A5BA9C6819

P304

Q34830633-A2C2009E-53D7-4E49-A6D4-A3E7A664F0A3

P31

Q34830633-48EAF787-9E4B-4E52-9BBF-01C4BDCB1BF2

P356

Q34830633-E2305741-73BC-464D-A3C8-974F8EF76BE2

P407

Q34830633-F0FF8E14-DF70-4EBF-8032-FFE12A7564E4

P433

Q34830633-E8A5787D-71B2-4AD6-8508-DB1FC1E21603

P478

Q34830633-F7B5B1C6-5741-4B65-8727-4C8E5904FDF3

P50

Q34830633-2B30A366-265C-430B-8C25-EE41C5A66A24

Q34830633-43723D04-7E23-45F4-AD72-2AD73E833EED

P577

Q34830633-37BAA841-BF3C-4149-AC7E-3A1BE6A3913D

P698

Q34830633-A33BEDCC-CEE9-4AED-AED6-65C36256C441

P921

Q34830633-F7B01247-61E9-48E6-91C2-66E18975AC3E

P932

Q34830633-2E326749-BEF3-4479-BB6D-E1CFDA4A46DF

P356

P1433

Journal of Clinical Investigation

P1476

Antisense oligonucleotide therapy for neurodegenerative disease

@en

P2093

Brett P Monia

http://www.w3.org/2001/XMLSchema#string

C Frank Bennett

http://www.w3.org/2001/XMLSchema#string

Chris M Ward

http://www.w3.org/2001/XMLSchema#string

Christian S Lobsiger

http://www.w3.org/2001/XMLSchema#string

Ed V Wancewicz

http://www.w3.org/2001/XMLSchema#string

Gene Hung

http://www.w3.org/2001/XMLSchema#string

Hongbing Wei

http://www.w3.org/2001/XMLSchema#string

Melissa McAlonis-Downes

http://www.w3.org/2001/XMLSchema#string

Richard A Smith

http://www.w3.org/2001/XMLSchema#string

Thomas P Condon

http://www.w3.org/2001/XMLSchema#string

P2860

Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1

Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

Killing the messenger: short RNAs that silence gene expression

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis

Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

Altered microtubule organization in small-calibre axons of mice lacking tau protein

P304

2290-2296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI25424

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Don W Cleveland

P577

2006-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16878173

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

1518790

http://www.w3.org/2001/XMLSchema#string